IntrinsicIntrinsic
← All summaries

Aspire Biopharma Holdings, Inc.

ASBP
Financials & Chart →

Business Summary

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company that develops and markets disruptive technology for novel sublingual delivery mechanisms, initially for known drugs and nutraceuticals . The company's core business model is to generate revenue through the development and marketing of these products, and it may also enter into license or collaboration agreements that include development funding, upfront and milestone payments, and/or royalties . Aspire primarily targets the heart attack and stroke prevention market, and also has products in the nutraceutical space .

Aspire's primary product focus is on its sublingual aspirin product, informally referred to as "Instaprin" . This patent-pending formulation aims to provide rapid sublingual absorption of aspirin into the bloodstream, bypassing the gastrointestinal tract and avoiding associated toxicity . The company has developed a high-dose version of this product using a micelle variation on its technology . A successful clinical trial for the high-dose sublingual aspirin was completed in July 2025, demonstrating faster aspirin bioavailability and quicker anti-coagulant properties compared to standard oral aspirin . These positive results will form the basis for a 505(b)(2) submission to the FDA planned for late 2026 .

Beyond aspirin, Aspire is developing several other products. These include a sublingually administered melatonin sleep-aid product in 3mg, 5mg, and 10mg doses, for which patent protection has been filed . The company has also developed working formulations for sublingually administered vitamins D, E, and K, also with patent protection filed . Additionally, Aspire is developing a sublingual ED (erectile dysfunction) product, with patent protection filed . In the nutraceutical space, Aspire has developed a single-serving sublingual pre-workout caffeine supplement, marketed under the trademark "Buzz Bomb" . Initial versions of this caffeine product began selling in the third quarter of 2025, and a manufacturing contract for 2,000,000 units was entered into, with marketing of these branded units commencing on January 15, 2026 . Other formulations under consideration or with filed patents include anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide .

For the fiscal year ended December 31, 2025, Aspire reported net revenue of $6,202 and a cost of revenue of $6,318 , resulting in a gross margin of $(116) . Operating expenses totaled $19,351,175 , leading to a loss from operations of $(19,351,291) . The net loss for the year was $(24,480,848) , with basic and diluted net loss per share of $(16.38) . As of December 31, 2025, the company had cash of $1,003,904 , an accumulated deficit of $27,258,081 , and a working capital deficit of $6,280,667 .

Comparing 2025 to 2024, net revenue increased from $0 in 2024 to $6,202 in 2025, as the company commenced product sales . General and administrative expenses significantly increased by $16,697,011, from $940,421 in 2024 to $17,637,432 in 2025, primarily due to professional services, consulting, stock-based compensation, and accounting . Research and development expenses rose by $779,558, from $144,356 in 2024 to $923,914 in 2025, reflecting increased personnel and supply costs for product development . Sales and marketing expenses also increased by $663,735, from $126,094 in 2024 to $789,829 in 2025, driven by investor awareness and product sampling . The company's net loss widened from $(1,309,872) in 2024 to $(24,480,848) in 2025 .

During the reported period, Aspire completed a reverse recapitalization on February 17, 2025, becoming Aspire Biopharma Holdings, Inc. . In connection with this, the company received proceeds of approximately $265,827 . A Securities Purchase Agreement on February 17, 2025, led to the issuance of two 20% original issue discount senior secured convertible debentures in an aggregate principal amount of $3,750,000 . An August 2025 Securities Purchase Agreement resulted in the sale of convertible notes with an aggregate principal amount of $9,687,500 for a subscription price of $7,750,000 . In October and November 2025, $9,523,683 of convertible notes were converted into 2,219,932 shares of common stock . The company also entered into a Second ELOC Agreement on November 11, 2025, granting it the right to direct Arena Business Solutions Global SPC II, Ltd. to purchase up to $100,000,000 in common stock over 24 months . Aspire regained compliance with Nasdaq's Bid Price Rule on February 3, 2026, and the MVLS Rule on February 18, 2026 .

Business Outlook

Aspire Biopharma Holdings, Inc. expects to generate revenue through developing and marketing drugs and nutraceuticals utilizing its novel sublingual delivery technology . The company may also pursue license or collaboration agreements with other companies, which could provide development funding, upfront and milestone payments, and/or royalties, becoming a significant source of revenue .

A major growth area for Aspire is its high-dose sublingual aspirin product, for which a 505(b)(2) submission to the FDA is planned for late 2026 . This submission will be supported by positive clinical trial results from July 2025, which demonstrated faster aspirin bioavailability and quicker anti-coagulant properties compared to standard oral aspirin . Following a positive FDA response to a pre-IND request on November 13, 2025, Aspire intends to conduct an additional clinical trial with approximately 32 healthy human volunteers, starting in approximately June 2026, to evaluate the pharmacodynamic effect on platelet inhibition . Further clinical trials are also being considered to differentiate the aspirin product based on TXB2 inhibition and gastrointestinal irritation for other therapeutic indications . The company is also exploring licensing possibilities for its aspirin products .

Another growth area is the expansion of its nutraceutical and other drug product pipeline. Aspire has developed a sublingually administered melatonin sleep-aid product in 3mg, 5mg, and 10mg doses, and has begun exploring licensing possibilities for it . Formulations for sublingually administered vitamins D, E, and K have also been developed . In the ED medication space, Aspire is developing a sublingual product, with FDA approval anticipated to take at least 2-3 years . The company has also launched a sublingual pre-workout caffeine supplement, "Buzz Bomb," with 2,000,000 units manufactured and marketing commencing on January 15, 2026 . Additionally, formulations for anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide have been created, with plans to take several of these to market as research and development, market conditions, and funding dictate .

Operationally, Aspire plans to continue contracting with third parties for manufacturing its product candidates for preclinical studies, clinical trials, and sale, with no current plans to build its own manufacturing facilities . To meet projected commercial manufacturing needs, current third-party manufacturers will need to increase their scale of production, or the company will need to secure alternate suppliers . Aspire has manufacturing agreements with Glatt for its high-dose sublingual aspirin product and Microsize for the next round of clinical trials for the high-dose aspirin for myocardial infarction . The company has not yet established a sales, marketing, or product distribution infrastructure for its aspirin products, as they are in early-stage clinical development . However, it plans to retain commercial rights in the United States and build a focused sales and marketing organization, or license its products to third parties for commercialization .

Aspire's future capital requirements are substantial and will depend on the timing and extent of spending for sales and marketing, and research and development efforts . The company intends to raise additional capital through issuances of additional equity under new and existing agreements . In February 2026, the company entered into a Securities Purchase Agreement, receiving net proceeds of approximately $6,777,206 after repayment of convertible notes and deal costs for purchases of convertible preferred stock . An Equity Line of Credit (ELOC) agreement entered into in November 2025 provides the right, but not the obligation, to direct Arena Business Solutions Global SPC II, Ltd. to purchase up to $100,000,000 in common stock over 24 months .

Risk Factors

Aspire faces several material risks, including its limited operating history and a history of incurring net losses in every year since inception, with expectations of continued substantial and increasing net losses in the foreseeable future, especially if difficulties in obtaining capital persist . The company will require substantial additional financing to achieve its goals, and a failure to obtain this necessary capital when needed could force delays, limitations, reductions, or termination of product development or commercialization efforts . Aspire relies on various intellectual property rights, including trademarks, and its failure to obtain or maintain these rights, or to prevent infringement, could adversely impact its competitive position and results of operations . The company's technology platforms and product candidates are based on novel technologies, and the regulatory approval pathway for sublingual aspirin is unproven, potentially never leading to marketable products or market acceptance even if approved . Aspire's business is highly dependent on the success of its lead product candidate, high-dose sublingual aspirin, which requires significant additional clinical testing before regulatory approval and commercial launch . Clinical development is a lengthy, expensive process with uncertain outcomes, and earlier study results may not predict future clinical trial success, potentially leading to delays or failures in demonstrating safety and efficacy . Undesirable side effects from product candidates could halt clinical development, prevent regulatory approval, limit commercial potential, or result in significant negative consequences . Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities . The company relies on third parties to conduct clinical trials and manufacture clinical product supplies, and any failure by these third parties to carry out contractual duties, meet deadlines, or comply with regulatory standards could stop, delay, or reduce the profitability of commercialization . Aspire currently lacks a marketing and sales organization and experience, and an inability to establish these capabilities or secure third-party agreements could prevent it from generating product revenue . International marketing efforts would expose the company to additional risks such as differing regulatory requirements, economic weakness, political instability, and foreign currency fluctuations . The biopharmaceutical industry is characterized by intense competition, and Aspire's operating results could suffer if it fails to compete effectively against companies with substantially greater resources . Misconduct by employees, contractors, or partners, including noncompliance with regulatory standards, could lead to significant fines, sanctions, or reputational harm . Product liability lawsuits, arising from clinical testing or commercialization, could result in substantial liabilities, require limitations on commercialization, or exhaust insurance and capital resources . The ongoing military action in Ukraine and the war between Israel and Hamas, and related economic sanctions, could materially and adversely affect Aspire's financial position and operations, particularly its ability to raise debt and equity finance . International trade disputes, including U.S. trade tariffs and retaliatory tariffs, could increase costs for tenants, impact global supply chains, and lead to inflationary pressures, adversely affecting the business .

Management Priorities

Management's message emphasizes Aspire's identity as an early-stage biopharmaceutical and supplements company focused on developing and marketing disruptive technology for novel sublingual delivery mechanisms, initially for known drugs . The company's growth strategy centers on generating revenue through product development and marketing, with potential for license or collaboration agreements to provide development funding and milestone payments . A key strategic priority is the advancement of its high-dose sublingual aspirin product, with positive clinical trial results from July 2025 forming the backbone of a planned 505(b)(2) submission to the FDA in late 2026 . Management also highlights the development of other products, including melatonin, vitamins D, E, and K, an ED medication, and the "Buzz Bomb" caffeine supplement, with marketing of 2,000,000 units of the caffeine supplement having commenced on January 15, 2026 . The company acknowledges its substantial future capital requirements, which will depend on the timing and extent of spending for sales, marketing, and research and development, and intends to raise additional financing through equity issuances . Management's assessment of the company's liquidity condition raises substantial doubt about its ability to continue as a going concern through the next twelve months .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Business Plan
  3. [3] Item 1, Business — Commercialization of Aspirin Products
  4. [4] Item 1, Business — Manufacturing
  5. [5] Item 1, Business — Our Products
  6. [6] Item 1, Business — Our Products
  7. [7] Item 1, Business — Manufacturing
  8. [8] Item 1, Business — Manufacturing
  9. [9] Item 1, Business — Current Development Status of Other Products
  10. [10] Item 1, Business — Current Development Status of Other Products
  11. [11] Item 1, Business — Current Development Status of Other Products
  12. [12] Item 1, Business — Current Development Status of Other Products
  13. [13] Item 1, Business — Current Development Status of Other Products
  14. [14] Item 1, Business — Current Development Status of Other Products
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Liquidity and Capital Resources
  23. [23] Item 7, MD&A — Liquidity and Capital Resources
  24. [24] Item 7, MD&A — Liquidity and Capital Resources
  25. [25] Item 7, MD&A — Gross Profit
  26. [26] Item 7, MD&A — General and Administrative
  27. [27] Item 7, MD&A — Research and Development
  28. [28] Item 7, MD&A — Sales and Marketing
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Overview
  31. [31] Item 7, MD&A — Liquidity and Capital Resources
  32. [32] Item 7, MD&A — Securities Purchase Agreement
  33. [33] Item 7, MD&A — Convertible Notes
  34. [34] Item 7, MD&A — Conversion of Notes
  35. [35] Item 7, MD&A — Liquidity and Capital Resources
  36. [36] Item 7, MD&A — Nasdaq Notices
  37. [37] Item 7, MD&A — Growth Strategy and Outlook
  38. [38] Item 7, MD&A — Growth Strategy and Outlook
  39. [39] Item 7, MD&A — Manufacturing
  40. [40] Item 7, MD&A — Manufacturing
  41. [41] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  42. [42] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  43. [43] Item 7, MD&A — Commercialization of Aspirin Products
  44. [44] Item 7, MD&A — Current Development Status of Other Products
  45. [45] Item 7, MD&A — Current Development Status of Other Products
  46. [46] Item 7, MD&A — Current Development Status of Other Products
  47. [47] Item 7, MD&A — Current Development Status of Other Products
  48. [48] Item 7, MD&A — Current Development Status of Other Products
  49. [49] Item 7, MD&A — Manufacturing
  50. [50] Item 7, MD&A — Manufacturing
  51. [51] Item 7, MD&A — Manufacturing
  52. [52] Item 7, MD&A — Commercialization of Aspirin Products
  53. [53] Item 7, MD&A — Commercialization of Aspirin Products
  54. [54] Item 7, MD&A — Liquidity and Capital Resources
  55. [55] Item 7, MD&A — Liquidity and Capital Resources
  56. [56] Item 7, MD&A — Liquidity and Capital Resources
  57. [57] Item 7, MD&A — Liquidity and Capital Resources
  58. [58] Item 1A, Risk Factors — Risks related to our Business
  59. [59] Item 1A, Risk Factors — Risks related to our Business
  60. [60] Item 1A, Risk Factors — Risks related to our Business
  61. [61] Item 1A, Risk Factors — Risks related to our Products and Their Development
  62. [62] Item 1A, Risk Factors — Risks related to our Products and Their Development
  63. [63] Item 1A, Risk Factors — Risks related to our Products and Their Development
  64. [64] Item 1A, Risk Factors — Risks related to our Products and Their Development
  65. [65] Item 1A, Risk Factors — Risks related to our Products and Their Development
  66. [66] Item 1A, Risk Factors — Risks related to our Products and Their Development
  67. [67] Item 1A, Risk Factors — Risks related to our Products and Their Development
  68. [68] Item 1A, Risk Factors — Risks related to our Products and Their Development
  69. [69] Item 1A, Risk Factors — Risks related to our Products and Their Development
  70. [70] Item 1A, Risk Factors — Risks related to our Products and Their Development
  71. [71] Item 1A, Risk Factors — Risks related to our Products and Their Development
  72. [72] Item 1A, Risk Factors — Risks related to our Business
  73. [73] Item 1A, Risk Factors — Risks related to our Business
  74. [74] Item 7, MD&A — Overview
  75. [75] Item 7, MD&A — Growth Strategy and Outlook
  76. [76] Item 7, MD&A — Manufacturing
  77. [77] Item 7, MD&A — Current Development Status of Other Products
  78. [78] Item 7, MD&A — Liquidity and Capital Resources
  79. [79] Item 7, MD&A — Liquidity and Capital Resources

Analysis on 5/22/2026